A study presented at the annual meeting of the American Society of Hematology concluded that tbo-filgrastim is similar to filgrastim for ASCT mobilization in patients with MM or NHL.
Tbo-filgrastim has been approved in Europe for all indications of filgrastim, the parent drug, but not in the United States. While filgrastim has been approved for treating neutropenia following chemotherapy as well as for mobilization of hematopoietic progenitors for autologous stem cell transplantation (ASCT), tbo-filgrastim has only been approved for neutropenia.
To compare the efficacy of the 2 treatments, a randomized phase 2 study was conducted at the Washington University School of Medicine, to evaluate the effect of filgrastim and tbo-filgrastim on peripheral blood (PB) CD34+ counts, CD34+ apheresis yield, toxicity, and post-ASCT engraftment in patients with multiple myeloma (MM) or non-Hodgkin lymphoma (NHL).
According to the study presented at the annual meeting of the American Society of Hematology, participants were randomized to the tbo-filgrastim or filgrastim group, and were administered either drug (10 µg/kg) once daily for 5 days. On the evening of day 4, plerixafor (0.24 mg/kg) was administered; apheresis was performed on Day 5. If a participant failed to achieve the target collection goal (5.0x106 cells/kg) on day 5, he/she continued to receive daily tbo-filgrastim/filgrastim, plerixafor, and apheresis for a maximum of 3 additional days. Participants who subsequently underwent ASCT were followed for platelet and neutrophil engraftment.
The study found similar post-mobilization PB CD34+ counts in both study arms: 20/µL for tbo-filgrastim and 22/µL for filgrastim (P = .647) on day 4. Pre-apheresis was for 94/µL for tbo-filgrastim and 92/µL for filgrastim (P = .726) on day 5. CD34+ apheresis yield was also similar between the arms: the median day 5 CD34+/kg apheresis yield was 10.9x106 for tbo-filgrastim and 12.0x106 for filgrastim (P = .88). Toxicity was similar between the arms as well, the study reported.
Based on the results the authors concluded that tbo-filgrastim is similar to filgrastim for ASCT mobilization in patients with MM or NHL.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More